Mykola Sosiukin/iStock via Getty Images Altimmune Inc. (NASDAQ:ALT) is completing a Phase 2 clinical trial of pemvidutide, an anti-obesity drug that appears to be able to bring important benefits to weight loss. The differentiating element compared to the competition seems to be the drug's ability to attack 74.5% fat mass and, if confirmed in the next phase 2 and phase 3 steps, could create a competitive moat against already approved drugs that act on the same GLP-1 hormone. The market prospects appear ...

NEW YORK, May 23, 2024 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Altimmune, Inc. ("Altimmune" or the "Company") (NASDAQ: ALT) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Altimmune investors who were adversely affected by alleged securities fraud between December 1, 2023 and April 26, 2024. Follow the link below to get more information and be contacted by a member of our team:https://zlk.com/pslra-1/altimmune-inc-lawsuit-submission ...

NEW YORK, May 22, 2024 /PRNewswire/ --WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Altimmune, Inc. (NASDAQ: ALT) between December 1, 2023 and April 26, 2024, both dates inclusive (the "Class Period"), of the important July 5, 2024 lead plaintiff deadline.SO WHAT: If you purchased Altimmune securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.WHAT TO DO NEX ...

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Altimmune, Inc. regarding a class action lawsuit alleging that the company made materially false and misleading statements about its lead product candidate, pemvidutide, during a specified class period [1][2]. Group 1 - The class period for the allegations is from December 1, 2023, to April 26, 2024 [1]. - The complaint claims that Altimmune overstated the potential of pemvidutide compared to competing glucagon-like peptide-1 agonists based on the results from the MOMENTUM Trial [1]. - It is alleged that the results of the MOMENTUM Trial were less significant for pemvidutide's clinical and commercial prospects than what was communicated to investors [1]. Group 2 - The lawsuit also contends that Altimmune's public statements were materially false and misleading, impacting the company's perceived prospects for finding a strategic partner for pemvidutide [1]. - Shareholders are encouraged to register for the class action by July 5, 2024, to participate in potential recovery [2]. - Once registered, shareholders will receive updates through a portfolio monitoring software regarding the case's progress [2]. Group 3 - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights against deceit and fraud [3]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements [3].

These stocks might not be small for too much longer.If you go to California's Redwood National Park, you can see the world's tallest tree -- a redwood called Hyperion that's over 380 feet tall. Like every other tree, though, Hyperion started as a small seed. Stocks can be like this, beginning small but growing to a giant size over time. Three Motley Fool contributors think they've found some monster stocks in the making you can buy right now. Here's why they picked Altimmune (ALT -10.00%), Axsome Therapeuti ...

The obesity market has garnered much interest lately, ever since Novo Nordisk (NVO) received FDA approval for its obesity drug Wegovy in 2021. It was only after a couple of years that the market gained a second entrant – Eli Lilly’s (LLY) Zepbound, which received FDA approval last year in November.Lilly and Novo have been registering top- and bottom-line growth, owing to the vastness of the total market size for obesity. The companies even achieved a market cap north of $500 billion. However, these firms ha ...

BENSALEM, Pa., May 16, 2024 /PRNewswire/ -- Law Offices of Howard G. Smith announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against Altimmune, Inc. ("Altimmune" or the "Company") (NASDAQ: ALT).Class Period: December 1, 2023 – April 26, 2024Lead Plaintiff Deadline: July 5, 2024Investors suffering losses on their Altimmune investments are encouraged to contact the Law Offices of Howard G. Smith to discuss their legal rights in this class actio ...

NEW YORK, May 16, 2024 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Altimmune, Inc. ("Altimmune" or the "Company") (NASDAQ: ALT) and certain officers. The class action, filed in the United States District Court for the District of Maryland, Southern Division, and docketed under 24-cv-01315, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Altimmune securities between December 1, 2023 and Ap ...

NEW YORK, May 15, 2024 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Altimmune, Inc. (NASDAQ: ALT) between December 1, 2023 and April 26, 2024, both dates inclusive (the "Class Period"), of the important July 5, 2024 lead plaintiff deadline.SO WHAT: If you purchased Altimmune securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.WHAT TO DO NE ...

Table of Contents Title of each class Trading Symbol(s) Name of each exchange on which registered Common stock, par value $0.0001 per share ALT The NASDAQ Global Market UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition p ...